Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rebates Redux: Medicare Drug Rebates Next?

This article was originally published in RPM Report

Executive Summary

Drug prices have lost their headline appeal. That has got to be a relief to pharma execs who have pipeline problems and patent expirations to deal with and don't need to be worried about bad publicity egging on Congress to price-control schemes. But there are new threats to drug prices brewing - and one of them is industry's old nemesis: government rebates.

You may also be interested in...

Rep. Waxman Can Move Follow-On Biologics As New Commerce Chairman

Follow-on biologics legislation will be crafted and brokered in the House by new Energy and Commerce Committee Chairman, Henry Waxman

Rep. Waxman Can Move Follow-On Biologics In New Role As Energy and Commerce Chairman

Victory over "Dean of the House" Dingell puts Waxman in the driver's seat to steer major legislation impacting the drug industry.

Adding Part D Protected Classes Could Cut Rebates 8%-31% – AMCP Study

Manufacturer rebates to Medicare Part D plans for diabetes therapies could be reduced by 8 percent if coverage of "substantially" all drugs in that category were required, according to a study commissioned by the Academy of Managed Care Pharmacy

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts